Experimental Therapeutics Directed at the Pathogenesis of Parkinson’s Disease
Experimental Therapeutics Directed at the Pathogenesis of Parkinson’s Disease
复制标题
针对帕金森病发病机制的实验疗法
DOI：
--
复制
发表时间：
1989
期刊：
影响因子：
--
通讯作者：
I. Shoulson
中科院分区：
文献类型：
--
作者：
I. Shoulson
左旋多巴治疗帕金森病（PD）的发展已经产生了实质性的临床和科学成果相关的神经退行性疾病的实验治疗。左旋多巴治疗对大多数PD患者的症状有益并延长了预期寿命。左旋多巴疗法和相关疗法的合理发展，以纠正PD中多巴胺能神经传递减少的后果，也已成为与神经递质缺乏相关的其他神经系统疾病的实验治疗的原型。尽管取得了这些进展，替代疗法的临床和科学局限性已变得越来越明显。症状性抗PD益处已被证明是短暂的，并且临床特征最终在进行性神经元变性的情况下加剧。致残性不良反应，如精神状态障碍、不自主运动和自主神经不稳定，进一步排除或限制了多巴胺能治疗的使用。合理的替代疗法在其他神经系统疾病中的应用受到神经退行性变引起的进行性和多递质紊乱的限制。
The development of levodopa therapy for Parkinson’s disease (PD) has spawned substantive clinical and scientific gains related to the experimental therapeutics of neurodegenerative disorders. Levodopa therapy has resulted in symptomatic benefit and increased life expectancy for the majority of PD patients. The rational development of levodopa therapy and related therapies to rectify the consequences of reduced dopaminergic neurotransmission in PD has also served as a prototype for the experimental therapeutics of other neurologic disorders associated with neurotransmitter deficits. In spite of these advances, the clinical and scientific limitations of replacement therapies have become increasingly evident. Symptomatic anti-PD benefits have proved transient, and clinical features intensify eventually in the setting of progressive neuronal degeneration. Disabling adverse effects, such as mental status disturbances, involuntary movements, and autonomic instability, further preclude or limit the use of dopaminergic therapies. The application of rational replacement therapy to other neurologic disorders has been constrained by the progressive and often multiple transmitter disturbances arising from neurode-generation.
影响因子：
56.9
作者：
DAMATO, RJ;LIPMAN, ZP;SNYDER, SH
通讯作者：
SNYDER, SH
羟基自由基对多巴胺的攻击。
DOI：
--
发表时间：
1985
期刊：
The Journal of biological chemistry
影响因子：
--
作者：
Slivka,A;Cohen,G
通讯作者：
Cohen,G